AR target genes include genes encoding for prostate-specific antigen (PSA), a kallikrein family serine protease and an important diagnostic marker for PCa [9], for prostate-specific membrane antigen (PSMA) overexpressed in most PCa and exploited as an imaging marker and PSMA-targeted therapies, for transmembrane protease serine 2 (TMPRSS2) often genetically fused to the ERG gene or other ETS family members acting as oncogenes, and for the lncRNA PCA3 a FDA-approved diagnostic marker [10–12]. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.